Gynaecology Working Group

Date: Friday 18 October 2019
Time: 08:00 – 10:00
Chairs: Emma Crosbie (UK), Denise Nebgen (USA), Neil Ryan (UK)

Time Session
8:00 – 8:20 The case for screening all endometrial cancer patients for Lynch syndrome – Neil Ryan (UK)
8:20 – 8:40 Cost/efficacy considerations on health care guidelines regarding gynecological cancer in Lynch syndrome – Tristan M. Snowsill (UK)
8:40 – 9:00 Ovarian cancer in path_BRCA carriers and consensus for revised clinical guideline to prevent gyn cancer – Denise Nebgen (USA)
9:00 – 9:08 Clinical translation of MMR protein expression analysis in uterine aspirates from Lynch syndrome women – Nuria Dueñas (Spain)
9:08 – 9:16 Tumorigenesis in Lynch syndrome-associated breast carcinoma: profiles of somatic alterations compared with colorectal and ovarian carcinomas – Noora Porkka (Finland)
9:16 – 9:24 Current management of gynecological cancers in Lynch syndrome: a Prospective Lynch Syndrome Database report – Mev Dominguez-Valentin (Norway)
9:24 – 9:32 Microsatellite instability in Lynch syndrome extra-colonic Cancers: why is there a greater incidence of MSS in endometrial cancers? – Peter Gawthorpe (UK)
9:32 – 9:40 Hereditary breast and ovarian cancer in Romania: genetic testing and counselling challenges in a Eastern European low-middle income country – Catana Andreea (Romania)
9:40 – 9:48 High frequency of BRCA 1 mutations in the series of 100 patients diagnosed with endometrial cancer before 50 years of age. – Dorota Nowakowska (Poland)
Top